Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0001577 (
adnexitis
)
232
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aztreonam
(
AZT
), a new monobactam antibiotic, was studied in obstetrics and gynecology with the following results. The tissue concentration of
AZT
in the female genital organs was relatively high at the portio vaginalis and the cervix uteri followed by at the ovary and the myometrium, but the distribution to the endometrium and the oviduct was a little poor. The concentration of
AZT
in the pelvic dead space exudate was highest at 2 hours after intravenous injection whereas it was highest at 5 hours after intravenous drip infusion. However, there was no significant difference in the concentration between intravenous injection and intravenous drip infusion and the distribution to the pelvic dead space exudate was relatively good.
AZT
was clinically administered to pyometra (3 cases), puerperal endometritis (3),
adnexitis
and endometritis (3), pelvioperitonitis (1), Bartholin's abscess (4) and purulent vulvitis (1), a total of 15 cases with an overall effective rate of 93.3%.
AZT
was microbiologically effective for Gram-negative bacteria such as E. coli and K. pneumoniae, but also effective for anaerobes and some Gram-positive bacteria, etc., for which MIC of
AZT
is high. With regard to safety of
AZT
, neither side effects nor abnormal laboratory findings were reported.
...
PMID:[Preclinical and clinical studies on aztreonam in obstetrics and gynecology]. 383 34
Aztreonam
(
AZT
), a new monobactam antibiotic, was basically and clinically applied to the field of obstetrics and gynecology, obtaining the following results. The pelvic dead space exudate level of
AZT
after 30 minutes-intravenous drip infusion of 1 g attained the peak of 22.66 micrograms/ml at 1 hour from initiation of infusion and thereafter declined gradually, contrasting the peak of 34.38 micrograms/ml of the cubital vein at 30 minutes. Total of 13 cases comprising 4 with intrauterine infection, 5 with
adnexitis
and 4 with pelveoperitonitis were intravenously treated with
AZT
at a dose of 1 g twice daily. The overall clinical results were excellent in 3 cases and good in 10 cases. No side effects were observed in any of the cases treated with
AZT
.
...
PMID:[Basic and clinical studies of aztreonam in the field of obstetrics and gynecology]. 383 41
Aztreonam
(
AZT
), a new monobactam antibiotic, was studied for clinical efficacy in the field of gynecologic infection.
AZT
was administered at a daily dose of 2 g in 2 divided doses by single shot intravenous injection. The subjects were patients with the following infections:
adnexitis
(6), pelvic peritonitis (5), endometritis (1) and wound abscess (1). Good response was seen in 10 patients out of 13. The overall efficacy rate of 76.9% was obtained. Slight increase in GOT, GPT and Al-P was seen in 1 case. It was normalized on 6th day after completion of the therapy. No notable side effects were observed.
...
PMID:[Clinical experience on aztreonam]. 383 42
